Ionis Pharmaceuticals (IONS) Share-based Compensation (2011 - 2026)

Ionis Pharmaceuticals' Share-based Compensation history runs 16 years deep, the most recent figure standing at $57.3 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 92.82% year-over-year to $57.3 million in Q1 2026; TTM through Mar 2026 was $241.9 million, a 220.55% increase from a year earlier, with the FY2025 full-year figure at $192.6 million, up 47.93% from the prior year.
• Share-based Compensation retreated to $57.3 million in Q1 2026 per IONS's latest filing, from $102.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $102.0 million in Q4 2025 and bottomed at $1.3 million in Q2 2025.
• The 5-year median for Share-based Compensation is $26.6 million (2023), against an average of $37.6 million.
• Across the five-year window, Share-based Compensation tumbled 95.12% in 2022 and jumped 1357.44% in 2023, its largest moves.
• Year by year, Share-based Compensation stood at $94.4 million in 2022, then rose by 2.94% to $97.1 million in 2023, then slumped by 62.78% to $36.1 million in 2024, then surged by 182.31% to $102.0 million in 2025, then slumped by 43.85% to $57.3 million in 2026.
• Per Business Quant, the three latest IONS Share-based Compensation figures stand at $57.3 million (Q1 2026), $102.0 million (Q4 2025), and $81.3 million (Q3 2025).